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Abstract
Introduction: The utility of reassessing anti-cyclic citrullinated peptide (anti-CCP) antibody status later in disease in
patients presenting with early undifferentiated inflammatory polyarthritis, particularly in those who test negative for
both anti-CCP and rheumatoid factor (RF) at baseline, remains unclear. We aimed therefore to determine the
stability of CCP antibody status over time and the prognostic utility of repeated testing in subjects with early
inflammatory polyarthritis (IP).
Methods: Anti-CCP and RF were measured at baseline and 5 years in 640 IP patients from the Norfolk Arthritis
Register, a primary care-based inception cohort. The relation between change in anti-CCP status/titer and the
presence of radiologic erosions, the extent of the Larsen score, and Health Assessment Questionnaire (HAQ) score
by 5 years was investigated.
Results: With a cut-off of 5 U/ml, 28% subjects tested positive for anti-CCP antibodies, 29% for RF, and 21% for
both at baseline. Nine (2%) anti-CCP-negative patients seroconverted to positive, and nine (4.6%) anti-CCP-positive
individuals became negative between baseline and 5 years. In contrast, RF status changed in 17% of subjects.
However, change in RF status was strongly linked to baseline anti-CCP status and was not independently
associated with outcome. Ever positivity for anti-CCP antibodies by 5 years did not improve prediction of
radiographic damage compared with baseline status alone (accuracy, 75% versus 74%). A higher baseline anti-CCP
titer (but not change in anti-CCP titer) predicted worse radiologic damage at 5 years (P < 0.0001), even at levels
below the cut-off for anti-CCP positivity. Thus, a titer of 2 to 5 U/ml was strongly associated with erosions by 5
years (odds ratio, 3.6 (1.5 to 8.3); P = 0.003).
Conclusions: Repeated testing of anti-CCP antibodies or RF in patients with IP does not improve prognostic value
and should not be recommended in routine clinical practice.
Introduction
The management of rheumatoid arthritis (RA) has under-
gone a seismic shift in recent years, with early intensive
intervention becoming the bench-mark. Diagnosing RA in
the early stages of its evolution may, however, be challen-
ging. The use of biomarkers to distinguish those patients
with inflammatory polyarthritis (IP) who will progress
rapidly from those who will follow a more benign course
is therefore of prime importance [1]. In relation to this,
the presence of anti-CCP antibodies has been found to be
a highly specific diagnostic marker for RA and a powerful
predictor of more severe disease, worse radiological and
functional outcomes and poorer response to treatment
[2-9]. However, the utility of retesting anti-CCP antibodies
later in disease in patients presenting with early undiffer-
entiated IP, particularly in those who test negative for
both anti-CCP and rheumatoid factor (RF) at baseline,
remains unclear. Most studies addressing the prognostic
role of anti-CCP antibodies in IP have relied on baseline
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testing alone, and evidence regarding the value of repeated
testing is lacking [2,3,6]. Nevertheless, it is not uncommon
in clinical practice for both anti-CCP and RF to be tested
on multiple occasions in an individual patient [10].
To answer this question, two key aspects must be
addressed. First, what is the likelihood that anti-CCP
antibody levels will change over the course of disease in
patients with IP? Second, does a change in anti-CCP
antibody status or titer associate with disease-severity
outcomes and, if so, would a lower threshold improve
prediction of adverse outcomes?
The appearance of anti-CCP antibodies may predate
the onset of RA, and anti-CCP titers have been shown
to increase in the years preceding diagnosis [11-13]. A
lower threshold for anti-CCP positivity may therefore be
more sensitive in predicting future RA development
[13]. The proportion of patients testing positive for RF
or anti-CCP tend to be much lower in cohorts with
early IP than in populations with established RA. How-
ever, data on serial autoantibody titers and rates of sero-
conversion over time in subjects with early IP are
extremely scarce [14]. In a cohort of 117 patients with
early arthritis, a nonsignificant increase was found in the
proportion of patients positive for anti-CCP and in anti-
CCP titers over a mean follow-up period of 32 months
[15]; whereas in a larger IP cohort of 545 patients, anti-
CCP titers decreased significantly between baseline and
1 year [16]. A recent systematic literature review con-
cluded that, although autoantibody seroconversion
appears to occur relatively infrequently, further studies
are needed to determine both the likelihood and prog-
nostic implications of anti-CCP or RF seroconversion in
subjects with undifferentiated IP [14].
Higher anti-CCP titers have been shown to predict
more-rapid radiographic progression in RA [5,17]. How-
ever, the prognostic importance of anti-CCP titer in
undifferentiated IP has not been established. Further-
more, it is not clear how change in anti-CCP titer over
time relates to treatment or outcomes [17-19]. In
patients with RA, one study found no correlation
between change in anti-CCP levels and changes in clini-
cal indices, whereas, in another, increasing anti-CCP
titers were associated with greater radiographic progres-
sion [17,18]. A study evaluating this relation in subjects
with IP found no significant association between first-
year change in anti-CCP titer and outcomes at 2 years
[16].
The aims of this study therefore were to assess the
long-term stability of anti-CCP antibody status in
patients with IP and to evaluate the relation between
anti-CCP titer and radiographic and functional outcome
to determine whether repeated antibody testing adds
any additional prognostic value.
Materials and methods
Patients
Subjects were recruited by the Norfolk Arthritis Register
(NOAR), a primary care-based inception cohort of
patients with IP, between 1990 and 1994. Details of
NOAR have been published previously [20]. In brief,
adults aged ≥ 16 years with swelling of two or more
joints lasting 4 weeks or longer were referred to NOAR.
Those subsequently diagnosed with a condition other
than RA, IP, psoriatic arthritis, or postviral arthritis
were excluded. Subjects were assessed by a trained
metrologist within 2 weeks by using a standardized
approach and then annually for 3 years and again at the
fifth year. Serum analysis for RF, CRP, and anti-CCP
was performed on blood samples taken at baseline and
5 years. Data gathered at baseline and year 5 included
joint counts for swelling and tenderness (in 51 joints)
and a patient-completed Health Assessment Question-
naire (HAQ). DAS28 was calculated by using CRP levels
and 28 tender- and swollen-joint counts (online at [21]).
Detailed information on the use of disease-modifying
anti-rheumatic drugs (DMARDS) and steroids was col-
lected. Radiographs of the hands and feet were per-
formed at 5 years and scored by using the Larsen
technique [22]. All radiographs were scored by two
observers with a third observer arbitrating in case of dis-
agreement [23]. The 1987 ACR classification criteria for
RA were applied at baseline and cumulatively at each
assessment. A blood sample for DNA extraction was
obtained at baseline; HLA DRB1 genotyping was under-
taken, and shared epitope (SE) defined, as described pre-
viously [24]. Written consent was obtained from all
patients, and the study was approved by the Norwich
Local Research Ethics Committee.
Serum testing
RF was measured by using a latex method, and a titer of
> 1:40 was classed as positive. CRP was measured by
using rate nephelometry. Anti-CCP testing was per-
formed by using the Axis-Shield DIASTAT kit accord-
ing to manufacturer’s instructions (Axis-Shield, Dundee,
U.K.) by using the recommended cut-off of > 5 U/ml as
positive. If the initial test gave an indeterminate value
close to the cut-off point, defined as a titer between 2
and 9 U/ml, the test was repeated, and the mean of the
two values taken. The assay is reliable up to concentra-
tions of 100 U/ml, and therefore, all values above this
were analyzed as 101 U/ml.
Details of anti-CCP testing
Subjects whose anti-CCP status changed between base-
line and 5 years were identified, and both baseline and
5-year samples were retested to minimize measurement
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error. In the event of a discrepancy between the original
and repeated results, the assay was repeated a further 2
times, and the mean of the measurements was taken.
Statistical analysis
Subjects were grouped according to stability of anti-CCP
or RF status between baseline and 5 years. The following
groups were defined for anti-CCP antibody status: CCP-/-;
CCP-/+; CCP+/-; CCP+/+, where the first sign (+ or -) indi-
cates status at baseline, and the second, the status by
5 years; similar groups were defined for RF status.
The groups were compared first for differences in base-
line characteristics by using either the c2 test or the
Fisher Exact test for dichotomous variables and the
Mann-Whitney U test for continuous variables. Second,
associations between the different autoantibody groups
and outcome by 5 years (presence of erosions, presence
of severe radiologic damage (highest tertile of Larsen
score, > 15), functional disability (HAQ score ≥ 1), and
indicators of ongoing disease activity, namely swollen
and tender joint count and DAS28)) were tested by using
logistic regression for binary outcomes, negative binomial
regression for counts, and median regression for continu-
ous non-normal outcomes. In the group which was auto-
antibody negative at baseline (CCP-/RF-), the subgroup
that became autoantibody positive (either anti-CCP and/
or RF positive) by 5 years was compared with those
which remained negative to determine whether differ-
ences existed in 5-year outcomes. Continuous variables
were compared by using the Mann-Whitney U test, and
categoric variables were compared by using the Fisher
Exact test.
Baseline anti-CCP titer was also evaluated as a continu-
ous variable for prediction of erosions and a Larsen score
> 15 by 5 years by using a receiver-operating characteris-
tic (ROC) curve method. Where subjects were split into
four categories of anti-CCP titer (≤ 2, > 2 to 5, > 5 to 20,
and > 20 U/ml), logistic regression models were used to
evaluate association with radiologic outcomes.
The Wilcoxon signed-rank test was used to investigate
changes in anti-CCP titer in individual patients. Correla-
tion between change in anti-CCP titers and both absolute
values and change in clinical variables was assessed by
using the Spearman rank correlation coefficient.
All analyses were undertaken by using Stata version




Between 1990 and 1994, 1,098 subjects were recruited to
NOAR. Included in this analysis were 640 (58%) with
available sera for RF and anti-CCP testing at both base-
line and 5 years. No significant differences between
those included and excluded were detected for any of
the baseline variables studied (data not shown). The 313
(49%) subjects fulfilled 1987 ACR criteria for RA at
baseline and 463 (72%) fulfilled them cumulatively over
the first 5 years of follow-up. Of the subjects, 25% had
received steroids by year 5, and 47% had been treated
with a DMARD. The DMARDs most commonly used
were sulfasalazine in 37% of patients, methotrexate in
22%, and gold in 7%. No subjects had received a biologic
agent by 5 years of follow-up, consistent with the time
period in which the samples were collected.
At baseline, 46 (7%) subjects were positive for RF alone,
59 (9%), positive for anti-CCP alone, and 136 (21%), posi-
tive for both antibodies. The overall distribution of auto-
antibody status was similar at 5 years; 42 (7%) were
positive for RF alone, 71 (11%), positive for anti-CCP
alone, and 124 (19%), positive for both.
Characteristics and 5-years outcome of patients with IP
who will never satisfy 1987 criteria for RA within the first
5 years of follow-up
At baseline, patients who will satisfy cumulatively 1987
ACR criteria for rheumatoid arthritis at any time point
during the first 5 years of follow-up differ significantly
from those who will never satisfy those criteria within the
same follow-up time (Table 1). The proportion of anti-
CCP-positive patients, the overall disease severity at base-
line and at 5 years, and the probability of treatment are
highly significantly higher in patients who will turn out
to have RA. Only eight patients of 177 (4.5%) with IP
who will not be classified as RA ("non-RA inflammatory
polyarthritis”) are positive for anti-CCP at baseline. After
5 years, only two of those patients have seroconverted
(Additional file 1, Supplemental table S4): one from anti-
CCP positive to negative, and one from anti-CCP nega-
tive to positive. Such a low number of anti-CCP-positive
patients prevents any powerful analysis of the differences
between seronegative and seropositive non-RA inflam-
matory polyarthritis (Additional file 1, Supplemental
table S4). For that reason, and because it is not possible
for practitioners at baseline to determine with high accu-
racy which patient will eventually be classified as RA
within the first 5 years of follow-up, we performed the
rest of the analysis presented here on the entire cohort of
640 patients, without stratification by the classification at
5 years.
Anti-CCP antibody status remains stable after up to 5
years of disease in patients with IP
Anti-CCP antibody status remained remarkably stable
between baseline and 5 years. Only nine (2%) anti-CCP-
negative patients seroconverted to positive, and nine
(4.6%) anti-CCP-positive individuals became negative
(Table 2). Several of these patients had anti-CCP titers
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close to the cut-off point of 5. The small number of sub-
jects in whom anti-CCP status changed limited the
power to perform reliable statistical comparisons with
those patients whose anti-CCP status remained stable.
Nevertheless, individuals converting from negative to
positive were more likely to be RF positive at baseline, to
have a higher baseline anti-CCP titer, and to possess at
least one copy of the shared epitope (SE) than did those
who remained negative (Table 2).
RF status is more likely to change, and change is
predicted by the baseline anti-CCP-antibody status
RF status was more likely to change between baseline and
5 years than was anti-CCP status (Additional file 1, Sup-
plemental table S1). 48 (10%) baseline RF-negative
patients tested positive at 5 years, and 64 (35%) of those
initially positive tested negative at 5 years. The most
notable factor associated with a change in RF status in
the first 5 years of disease was baseline anti-CCP status
(Additional file 1, Supplemental table S1). RF status was
8 times more likely to change in patients with a discor-
dant baseline autoantibody status (RF+/anti-CCP- or RF-/
anti-CCP+) than in those who were either negative or
positive for both auto-antibodies (odds ratio (OR) 8.2;
95% CI, 4.9 to 13.7; P < 0.00001). Thus, RF-negative indi-
viduals who seroconverted to RF positive were more
likely to be anti-CCP positive at baseline than were those
who remained RF negative (OR, 7.6; 95% CI, 3.8 to 15.3);
similarly, those who converted from RF positive to RF
negative were more likely to be anti-CCP negative at
baseline than were those who remained RF positive (OR,
7.4; 95% CI, 3.5 to 15.6, (Additional file 1, Supplemental
table S1). These associations remained significant after
adjustment for other baseline variables and DMARD
treatment.
Baseline anti-CCP status remains the best predictor of
5-year outcome
Individuals changing from anti-CCP negative to positive
were more likely to have erosions and a high Larsen
score at 5 years than were those who remained negative
(Table 2). They were also more likely to have been trea-
ted with a DMARD, which, given that anti-CCP status
was not known at the time of treatment, is likely to be a
marker of disease severity. In contrast, individuals chan-
ging from anti-CCP positive to negative had radiographic
Table 1 Baseline characteristics and 5-year outcome of patients who will satisfy cumulatively 1987 ACR criteria for
rheumatoid arthritis at any time during the first 5 years of follow-up, versus those who will not
Classification Satisfying 1987 ACR criteria within the first
5 years
(n = 463; 72%)






Age (onset) 55.4 (45.8, 65.4) 47.7 (34.3, 57.9) 3.6E-
09
Female 305 (66%) 114 (64%) 0.73
Symptom duration 5.3 (2.6, 11.3) 4.5 (1.9, 9.0) 0.01
Anti-CCP +ve 187 (40.4%) 8 (4.5%) 1.2E-
18
Anti-CCP titer 1.6 (0.7, 42.5) 0.8 (0.5, 1.4) 6.4E-
16
HAQ 0.875 (0.375, 1.5) 0.25 (0, 0.625) 5.8E-
24
DAS28 4.4 (3.5, 5.4) 2.8 (2.1, 3.6) 5.2E-
33
5-year outcome
HAQ 1.125 (0.375, 1.75) 0.25 (0, 0.625) 4.1E-
24
DAS28 2.8 (2.0, 3.9) 2.0 (1.15, 2.4) 1.3E-
14
Erosions 220 (56.9%) 12 (8.8%) 3.1E-
22
Larsen score 12 (2, 31) 1 (0, 4) 9.3E-
21
DMARD received 278 (60.0%) 23 (13.1%) 2.2E-
26
Continuous variables expressed as median (interquartile range) and compared by using the Mann-Whitney U test. Categoric variables expressed as number
(percentage) and compared by using the c2 test. ACR, American College of Rheumatology criteria for rheumatoid arthritis; DAS, disease activity score; HAQ,
Health Assessment Questionnaire.
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and functional outcomes at 5 years similar to those that
remained positive, although a trend towards lower dis-
ease activity appeared, as assessed by DAS28 and swol-
len-joint count (Table 2). Combined baseline and 5-year
anti-CCP measurements did not improve the sensitivity
or specificity for detection of radiographic joint damage
or functional impairment (HAQ ≥ 1) compared with
baseline anti-CCP status alone (Table 3). Clinical out-
comes at 5 years differed in patients whose RF status
changed between baseline and 5 years compared with
those who remained consistently RF negative or RF posi-
tive (Additional file 1, Supplemental table S2). However,
these differences were largely accounted for by differ-
ences in anti-CCP status at baseline. After adjustment for
the presence of anti-CCP antibodies at baseline, no sig-
nificant differences in 5-year outcomes were found
between the patients who remained RF positive at 5 years
and the 35% who converted from RF positive to negative
(Additional file 1, Supplemental table S2).
Failing to identify individuals who test autoantibody
negative at baseline but later become seropositive is a
potential clinical concern; therefore, the 399 individuals
testing negative for both RF and anti-CCP at baseline
were analyzed as a separate group. Only 1.5% of these
patients converted to become anti-CCP positive between
baseline and 5 years. More (6.7%) converted to become
RF positive; however, most outcomes at 5 years were
not significantly different in patients becoming autoanti-
body positive compared with those that remained auto-
antibody negative (Additional file 1, Supplemental table
S3). The exception is that patients who became autoan-
tibody positive by 5 years were more likely to have
received a DMARD than were those remaining negative;
this may reflect that those patients had other features of
severe disease.
Baseline anti-CCP titer predicts erosive joint damage at
5 years
A higher baseline anti-CCP antibody concentration
among anti-CCP-negative individuals was the strongest
predictive factor for conversion to anti-CCP positive in
the first 5 years of disease (Table 2). We therefore
Table 2 Baseline characteristics and 5-year outcome according to baseline and 5-year anti-CCP status
Anti-CCP negative at baseline Anti-CCP positive at baseline
5-year anti-CCP status Anti-CCP negative
(n = 436, 98%)
CCP-/-
Anti-CCP positive
(n = 9, 2%)
CCP-/+
P value Anti-CCP negative
(n = 9, 4.6%)
CCP+/-
Anti-CCP positive




Age (n = 640) 51.9 (40.7, 63.1) 47.1 (42.8, 57.1) 0.39 53.4 (50.1, 58.5) 56.1 (48.1, 65.0) 0.46
Female (n = 640) 293 (67%) 7 (78%) 0.72 5 (56%) 114 (61%) 0.74
Symptom duration (n = 596) 4.9 (2.1, 10.4) 3.6 (2.5, 10.1) 0.77 4.8 (3.1, 6.1) 5.3 (2.9, 10.9) 0.82
RF +ve (n = 640) 43 (9.8%) 3 (33%) 0.06 6 (67%) 130 (70%) 1.0
Anti-CCP titer (n = 596) 0.8 (0.5, 1.4) 1.5 (1.4, 3.8) 0.0004 16.2 (13.0, 41.6) 66.8 (32, 101) 0.005
SE - 1 or 2 copies (n = 593) 213 (53%) 7 (100%) 0.017 7 (88%) 138 (78%) 1.0
HAQ (n = 639) 0.6 (0.3, 1.1) 1.1 (0.6, 1.3) 0.13 0.8 (0.4, 1.5) 0.9 (0.4, 1.6) 0.88
CRP (n = 591) 3 (0, 11) 4 (1, 14) 0.73 10 (6, 16) 11 (4, 26) 0.83
Swollen joints (n = 640) 6 (2, 12) 11 (5, 13) 0.12 5 (2, 10) 8 (4, 17) 0.22
Tender joints (n = 640) 7 (2, 16) 15 (6, 24) 0.11 7 (5, 8) 9 (4, 16) 0.24
DAS28 (n = 591) 3.7 (2.7, 4.8) 5.1 (3.2, 5.5) 0.22 4.0 (3.2, 4.5) 4.5 (3.5, 5.4) 0.30
Current smoker (n = 640) 102 (23%) 2 (22%) 1.0 0 (0) 56 (30%) 0.06
Fulfils ACR criteria (n = 640) 168 (39%) 4 (44%) 0.74 6 (67%) 135 (73%) 0.71
Outcome year 5
Erosions (n = 523) 95 (27%) 6 (85%) 0.002 6 (75%) 125 (80%) 0.66
Larsen score (n = 521) 2 (0, 10) 35 (19, 71) 0.001 28 (5, 44) 28 (11, 43) 0.80
HAQ (n = 639) 0.6 (0, 1.4) 1.6 (0.1, 2.1) 0.24 1.1 (0.4, 1.8) 1.1 (0.5, 2) 0.40
Swollen joints (n = 475) 1 (0, 3) 2 (1, 5) 0.07 1 (0, 2) 3 (0, 8) 0.04
Tender joints (n = 475) 1 (0, 6) 3 (0, 11) 0.67 2 (0, 4) 3(0, 11) 0.20
DAS28 (n = 463) 2.2 (1.4, 3.1) 2.9 (1.6, 4.2) 0.25 1.7 (1.2, 3.4) 3.3 (2.4, 4.4) 0.03
DMARD received (n = 639) 124 (29%) 8 (89%) < 0.0001 7 (78%) 162 (87%) 0.34
Fulfils ACR criteria (n = 639) 268 (62%) 8 (89%) 0.16 8 (89%) 179 (96%) 0.32
Continuous variables expressed as median (interquartile range) and compared by using the Mann-Whitney U test. Categoric variables expressed as number
(percentage) and compared by using the Fisher Exact test. ACR, American College of Rheumatology criteria for rheumatoid arthritis; CRP, C-reactive protein;
DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug;
HAQ, Health Assessment Questionnaire; RF, rheumatoid factor.
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examined the relation between baseline anti-CCP titer
and radiographic and functional outcome. Baseline anti-
CCP concentration was significantly associated with the
presence and severity of erosions (Table 4). Classifying
patients according to anti-CCP titer revealed a dose-
response relation between increasing baseline anti-CCP
titers and the presence and severity of erosions at 5
years (Table 5). Even baseline anti-CCP titers between 2
and 5 U/ml were highly significantly associated with
radiologic outcome at 5 years. Consequently, reducing
the cut-off threshold for anti-CCP titer to 2 U/ml
improved the sensitivity for predicting erosions from
53% to 59%. However, the corresponding loss of specifi-
city meant that the overall accuracy remained similar to
the standard cut-off of 5 U/ml (Table 6).
Change in anti-CCP titer between baseline and 5 years
does not correlate with clinical outcomes
A small but statistically significant increase was found in
anti-CCP titer between baseline and 5 years in this
cohort. The median absolute change was 0.11 (IQR, -0.5
to 0.77; P = 0.0007), which equated to a median percen-
tage increase of 10% (IQR, -34% to 95%). Change in anti-
CCP antibody titer was negatively correlated with the
baseline titer (Spearman rho, -0.24 for absolute change
and -0.4 for percentage change; P < 0.00001; that is, the
higher the baseline anti-CCP titer, the less likely it was to
increase). However, no correlation between change in
anti-CCP titer and any of the markers of disease activity
or severity at 5 years was detected. Changes in HAQ,
DAS28, swollen and tender joint count and CRP between
baseline and 5 years likewise did not correlate with
change in anti-CCP concentration (data not shown). This
remained true after adjustment for baseline anti-CCP
concentration and DMARD treatment.
Discussion
The key message of this study is that anti-CCP antibody
status remains stable up to 5 years after disease onset in
patients with IP. Patients switching from anti-CCP positive
to negative retained the disease characteristics of persis-
tently anti-CCP-positive patients. In contrast, 5-year radio-
graphic outcomes were significantly worse in individuals
converting from anti-CCP negative to positive, compared
with those who remained negative; however, only 1.5% of
patients negative for both anti-CCP and RF at baseline had
converted to anti-CCP positive at 5 years. Repeating anti-
CCP antibody measurement at 5 years added no additional
predictive value in detection of radiographic damage or
functional disability over baseline anti-CCP status alone.
Consistent with previous studies, RF status was more
likely to change over time, with a lower proportion of
subjects testing positive for RF at 5 years than at presen-
tation [15,16]. However, baseline anti-CCP status was a
strong predictor of change in RF status, and after
accounting for the effect of anti-CCP, change in RF status
in either direction was not significantly associated with
clinical outcomes. This is in keeping with our previous
findings in this cohort that anti-CCP antibodies predict
more-severe disease irrespective of RF status [8,25].
Table 3 Sensitivity, specificity and likelihood ratios for presence of radiographic damage and functional disability at 5
years according to baseline and 5-year autoantibody status
Autoantibody status Erosions Larsen score > 15 HAQ ≥ 1
Sensitivity Specificity Accuracy LR Sensitivity Specificity Accuracy LR Sensitivity Specificity Accuracy LR
Anti-CCP+
Baseline 0.56 0.89 0.74 5.0 0.65 0.85 0.79 4.3 0.41 0.78 0.61 1.8
Year 5 0.56 0.89 0.75 5.1 0.66 0.86 0.79 4.5 0.41 0.78 0.61 1.8
Base or Year 5 0.59 0.88 0.75 5.1 0.69 0.85 0.79 4.5 0.43 0.77 0.62 1.8
RF+
Baseline 0.44 0.84 0.67 2.8 0.50 0.82 0.71 2.7 0.36 0.77 0.59 1.6
Year 5 0.40 0.84 0.65 2.5 0.42 0.81 0.68 2.2 0.36 0.82 0.61 1.9
Base or Year 5 0.54 0.76 0.67 2.3 0.60 0.74 0.69 2.3 0.45 0.72 0.60 1.6
Logistic regression model; LR, likelihood ratio.
Table 4 Logistic regression model exploring association between baseline anti-CCP titer and radiographic and
functional outcome at 5 years
5-year outcome OR (95% CI) P Adjusted ORa Adjusted Pa
Erosions 1.03 (1.02, 1.04) < 0.0001 1.03 (1.01, 1.03) < 0.0001
Larsen score > 15 1.03 (1.02, 1.03) < 0.0001 1.02 (1.01, 1.03) < 0.0001
HAQ ≥ 1 1.01 (1.01, 1.02) < 0.0001 1.00 (0.99, 1.01) 0.47
aAdjusted for age, gender, symptom duration and CRP, RF, HAQ, and swollen- and tender-joint counts at baseline. OR, odds ratio; CI, confidence interval. Baseline
anti-CCP titer was available in 596 patients. ACR, American College of Rheumatology criteria for rheumatoid arthritis; DAS, disease activity score; HAQ, Health
Assessment Questionnaire.
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Table 5 Logistic regression for 5-year radiographic damage according to categories of baseline anti-CCP titer
Anti-CCP titer Erosions Larsen score ≥ 15
No with erosions/
total in group (%)
OR (95% CI) P value Adjusted OR (95% CI)a P valuea No with Larsen ≥
15/total in group
(%)
OR (95% CI) P value Adjusted OR (95% CI)a P valuea
≤ 2 85/324 (26%) Ref - Ref - 47/323 (15%) Ref - Ref -
> 2 to 5 14/25 (56%) 3.6 (1.5, 8.3) 0.003 3.4 (1.2, 9.8) 0.02 11/25 (44%) 4.6 (1.9, 11) 0.0001 4.3 (1.4, 13) 0.009
> 5 to 20 16/22 (73%) 7.5 (2.7, 20) < 0.0001 3.8 (1.3, 12) 0.02 14/22 (64%) 10.3 (3.9, 27) < 0.0001 5.3 (1.7, 16) 0.003
> 20 94/116 (81%) 12.4 (6.6, 22) < 0.0001 9.0
(4.4, 18)
< 0.0001 77/115 (67%) 11.9 (6.7, 21) < 0.0001 9.7 (4.7, 20) < 0.0001















Consistent with the known specificity of a positive anti-
CCP status for RA and with its strong association with dis-
ease severity, patients with IP who will not satisfy the 1987
criteria for RA at any time during the first 5 years of fol-
low-up were much less likely to be anti-CCP positive and
displayed a much milder disease course. However, it is
now impossible for practitioners to predict accurately at
baseline which patient will prospectively go on to satisfy
cumulatively the 1987 ACR criteria for RA within the 5
first years of follow-up. This should be, however, improved
with the use of the 2010 ACR/EULAR criteria.
Baseline anti-CCP titer predicted both the presence
and severity of erosive joint damage at 5 years in this
cohort. A dose-response relation was observed, and indi-
viduals with a baseline anti-CCP concentration of more
than 4 times the upper limit of normal were 10 times
more likely to have a Larsen score above 15 (highest ter-
tile) at 5 years as were those with a baseline anti-CCP
titer of less than 2 (Table 5). Consistent with this, higher
anti-CCP antibody levels have been found to associate
with increased disease activity and radiographic progres-
sion in patients with RA [5,17,26]. However, a previous
study investigating this relation in subjects with undiffer-
entiated IP found no significant association between
baseline anti-CCP concentration and DAS28, HAQ, or
radiographic progression at 2 years [16]. The disparity
with our results may relate to the short follow-up time in
that study, as the strength of correlation between baseline
anti-CCP titer and clinical indices has been shown to
increase gradually in the first 5 years of disease in
patients with early RA [17]. In support of our findings,
higher anti-CCP titers predicted development of persis-
tent arthritis in patients with IP [27]. Lowering the
threshold for anti-CCP positivity marginally improved
the predictive value for erosive disease in our cohort, but
at the cost of loss of specificity, which is similar to the
findings of Mjaavatten et al. [27] for prediction of persis-
tent arthritis. Insufficient evidence exists to recommend
altering the threshold for anti-CCP positivity; however,
these findings highlight the importance of considering
the absolute anti-CCP titer when evaluating the likely
prognosis in patients with early IP [13,27].
In keeping with previous studies, we found no significant
associations between change in anti-CCP titers and 5-year
clinical outcomes [16,17]. It is not clear whether anti-CCP
titers are affected by DMARD treatment, and study find-
ings have been inconsistent [17-19]. We included an
adjustment for ever having received a DMARD, which did
not materially alter our findings; however, we cannot
exclude that DMARD treatment may have influenced
associations between change in anti-CCP concentrations
and clinical outcomes. Nevertheless, available data suggest
that any associations between variation in anti-CCP titer
and disease severity are relatively weak and are unlikely to
add significant prognostic information over that of base-
line anti-CCP titer alone.
The proportion of patients positive for anti-CCP (30%)
or RF (26%) at 5 years was much lower than is typically
seen in cohorts with established RA, even though 73% of
patients fulfilled ACR criteria for RA by 5 years. These
percentages are similar to those observed in other early
arthritis cohorts [14]. Our findings indicate that this dis-
crepancy is unlikely to be due to a large proportion of sub-
jects converting to autoantibody positivity in later disease.
An alternative explanation may be that seronegative indi-
viduals are more likely to have milder disease and there-
fore are underrepresented in hospital-based cohorts with
established RA.
Strengths of this study include the large sample size
tested in the analysis, the availability of serum samples at
baseline and 5 years, and the repeated testing of borderline
samples to ensure the most accurate results. A potential
weakness is the fact that no information was available
regarding RF or anti-CCP status in the intervening years,
so it is possible that “ever positive” status is a better pre-
dictor of outcome. However, given the stability observed
for anti-CCP status over a 5-year period, it is unlikely to
vary to a greater extent over the intervening years.
Conclusions
Anti-CCP antibody status is unlikely to change over time
in patients with early IP, and 5-year autoantibody testing
adds no prognostic value over baseline measurement
alone. Our findings, in conjunction with those of previous
Table 6 Prediction of radiographic damage at 5 years for different cut-off levels of baseline anti-CCP titer
Anti-CCP titer cut-off Erosions Larsen score ≥ 15
Sensitivity Specificity Accuracy LR+ve LR-ve Sensitivity Specificity Accuracy LR+ve LR-ve
1 0.80 0.54 0.65 1.7 0.4 0.88 0.52 0.63 1.8 0.2
2 0.59 0.86 0.74 4.2 0.5 0.69 0.82 0.78 3.8 0.4
3 0.56 0.89 0.75 5.0 0.5 0.66 0.85 0.79 4.4 0.4
4 0.54 0.90 0.74 5.3 0.5 0.62 0.86 0.79 4.6 0.4
5 0.53 0.90 0.74 5.2 0.5 0.61 0.86 0.79 4.5 0.5
10 0.50 0.91 0.73 5.5 0.6 0.57 0.87 0.78 4.5 0.5
LR+ve, positive likelihood ratio; LR-ve, negative likelihood ratio.
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studies, provide no evidence of a benefit of routine retest-
ing of anti-CCP antibodies or RF in patients with IP
[15,16]. Repeated testing may nevertheless be useful in
specific clinical scenarios, such as in patients negative for
both RF and anti-CCP at presentation but with severe dis-
ease, in whom autoantibody status may influence treat-
ment decisions, such as the use of Rituximab, which is less
effective in seronegative patients. This study additionally
demonstrates that higher anti-CCP titer at presentation in
patients with IP predicts both development and severity of
erosive disease, even at levels below the cut-off for anti-
CCP positivity. Absolute anti-CCP titer should therefore
be considered both a diagnostic and prognostic marker in
patients with early IP [13,27].
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